Equities research analysts at Wedbush reduced their Q1 2025 earnings per share estimates for shares of Voyager Therapeutics ...

Analysts have set 12-month price targets for Voyager Therapeutics, revealing an average target of $18.93, a high estimate of $30.00, and a low estimate of $5.73. This current average represents a ...

Bank of New York Mellon Corp lessened its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR – Free Report) by 22.5% in the 4th quarter, according to its most recent filing with the SEC. The firm ...

Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Voyager Therapeutics (VYGR) to $10 from $12 and keeps an Overweight rating on ...

Voyager Therapeutics announced positive results from the single ascending dose (SAD) trial of its investigational anti-tau antibody, VY7523, which demonstrates safety, tolerability, and dose ...

Canaccord lowered the firm’s price target on Voyager Therapeutics (VYGR) to $12 from $14 and keeps a Buy rating on the shares. The firm said ...

Pete Stavropoulos; Analyst; Cantor Fitzgerald & Co. Good afternoon and welcome to Voyager Therapeutics fourth-quarter and year-end 2024 financial results conference call. (Operator Instructions ...

The latest price target for Voyager Therapeutics (NASDAQ:VYGR) was reported by Canaccord Genuity on March 13, 2025. The analyst firm set a price target for $12.00 expecting VYGR to rise to within ...

LEXINGTON, Mass. (AP) — LEXINGTON, Mass. (AP) — Voyager Therapeutics Inc. (VYGR) on Tuesday reported a loss of $34.5 million in its fourth quarter. On a per-share basis, the Lexington ...